HGEN News and Press, Humanigen Inc. From 03/04/22

Gainers: Atreca (NASDAQ:BCEL) +20%. Alignment Healthcare (NASDAQ:ALHC) +16%. Puma Biotechnology (NASDAQ:PBYI) +15%. Humanigen (NASDAQ:HGEN) +13%. agilon health (NYSE:AGL) +8%. Losers: DBV Technologies (NASDAQ:DBVT) -22%. Ocugen (NASDAQ:OCGN) -20%.  ...

Clinical-stage biotech, Humanigen (NASDAQ:HGEN) has added ~6% in the pre-market after two of the senior officers of the company, including Chief Executive Cameron Durrant, disclosed insider purchases through SEC filings on Friday. On Mar. 02, Cameron has bought 40,000 company s...

Sweetgreen (NYSE:SG) +18% on Q4 results. Funko FNKO +18% on Q4 earnings beats, upside FY22 guidance FedNat Holding (NASDAQ:FNHC) +13% on Q4 results. Indonesia Energy (NYSE:INDO) +18%. The Gap (NYSE:GPS) +7% on Q4 results. Humanigen (NASDAQ:HGEN) +6%. ...

Humanigen press release (NASDAQ:HGEN): FY GAAP EPS of -$0.53 beats by $0.24. Revenue of $1.04M (+235.5% Y/Y) misses by $132.52M. As of December 31, 2021, the company had cash and cash equivalents of $70.0M. For further details see: Humanigen GAAP EPS of -$0.53 beats by $0.24, revenue of...

Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called “cytokine storm” with its lead drug candidate, lenzilumab, today reported financial results for the year ended December...

Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced today that management will present and participate at several events in March with investors, analysts,...

Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced today that Timothy E. Morris, COO/CFO, will be presenting at the upcoming 2022 BIO CEO & Investor...

Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced today that lenzilumab is now available for certain hospitalized COVID-19 patients through its newly-lau...

Burlingame, Calif.-based Humanigen (NASDAQ:HGEN) is collaborating with Cenexi to make the French company a preferred supplier for its potential COVID-19 therapy lenzilumab in France and the EU. The companies will execute an agreement under which Cenexi will provide aseptic fill and finish ser...

Cenexi to Become Preferred Drug Product Supplier for France and the European Union Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine s...